Alnylam Pharmaceuticals (ALNY) EBITDA (2009 - 2025)
Alnylam Pharmaceuticals (ALNY) EBITDA from Jun 30, 2009 to Dec 31, 2025. The TTM Alnylam Pharmaceuticals (ALNY) EBITDA is $556M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Annual EBITDA change of Alnylam Pharmaceuticals (ALNY)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | $556M | -556.87% |
| 2024 | -$122M | -47.18% |
| 2023 | -$231M | -69.09% |
| 2022 | -$746M | +11.03% |
| 2021 | -$672M | -15.83% |
| 2020 | -$798M | -13.50% |
| 2019 | -$923M | +15.08% |
| 2018 | -$802M | +64.75% |
| 2017 | -$487M | +18.87% |
| 2016 | -$409M | +47.84% |
| 2015 | -$277M | -29.54% |
| 2014 | -$393M | +375.21% |
| 2013 | -$83M | -31.32% |
| 2012 | -$120M | +142.34% |
| 2011 | -$50M | +26.99% |
| 2010 | -$39M | -7.10% |
| 2009 | -$42M | +90.50% |
| 2008 | -$22M | N/A |